Drug Profile
GSK 568893A
Alternative Names: GSK-568893A; Human papillomavirus (types 16, 18, 31, 45) L1 virus-like particle vaccine - GSK; Human papillomavirus (types 16, 18, 31, 45) L1 VLP vaccine - GSK; Human papillomavirus quadrivalent (types 16, 18, 31, 45) recombinant vaccine - GSK; Tetravalent HPV L1 16/18/31/45 virus-like particle vaccine - GSKLatest Information Update: 28 Jul 2023
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Class Cancer vaccines; Papillomavirus vaccines; Virus-like particle vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Cervical cancer; Human papillomavirus infections
Most Recent Events
- 12 May 2014 Discontinued - Phase-II for Cervical cancer in Belgium (IM)
- 12 May 2014 Discontinued - Phase-II for Cervical cancer in USA (IM)
- 12 May 2014 Discontinued - Phase-II for Human papillomavirus infections in Belgium (IM)